Published in Cancer Weekly, December 18th, 2001
Enchira recorded a net loss for the quarter ended September 30, 2001 of $2,466,133, or $0.31 per share compared with $1,577,064 for the same quarter in 2000, or $0.28 per share. This increased net loss was mainly due to amounts owed as a result of the arbitration with Maxygen. On November 3, 2001, the arbitrator issued a final ruling requiring Enchira to pay a portion of Maxygen's attorneys' fees in the amount of $556,826 and the arbitration costs in the amount of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.